daprodustat 1 MG Oral Tablet [Jesduvroq]

RxCUI: 2628221
RxNorm name: daprodustat 1 MG Oral Tablet [Jesduvroq]
Display name: daprodustat 1 MG Oral Tablet [Jesduvroq]
Full name: daprodustat 1 MG Oral Tablet [Jesduvroq]
Term type: SBD
Status: DailyMed mapping
Updated: 2026-06-04 23:39:23

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Jesduvroq	DAPRODUSTAT	GlaxoSmithKline LLC	d82aa06e-5a33-4844-99b7-4701313455a4	2023-08-30	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2628221

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set ID	RxNorm string	TTY	SPL version	Label	Effective
d82aa06e-5a33-4844-99b7-4701313455a4	daprodustat 1 MG Oral Tablet [Jesduvroq]	SBD	5	These highlights do not include all the information needed to use JESDUVROQ safely and effectively. See full prescribing information for JESDUVROQ. JESDUVROQ (daprodustat) tablets, for oral use Initial U.S. Approval: 2023	20230830
d82aa06e-5a33-4844-99b7-4701313455a4	Jesduvroq 1 MG Oral Tablet	PSN	5	These highlights do not include all the information needed to use JESDUVROQ safely and effectively. See full prescribing information for JESDUVROQ. JESDUVROQ (daprodustat) tablets, for oral use Initial U.S. Approval: 2023	20230830
d82aa06e-5a33-4844-99b7-4701313455a4	Jesduvroq 1 MG Oral Tablet	SY	5	These highlights do not include all the information needed to use JESDUVROQ safely and effectively. See full prescribing information for JESDUVROQ. JESDUVROQ (daprodustat) tablets, for oral use Initial U.S. Approval: 2023	20230830